ArticleCancers2021
Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of physical therapy for lower limb lymphedema in gynecological cancer survivors: a systematic review of randomized controlled trials.Frontiers in oncology · 2026Pooled it
- Risk factors for lower limb lymphedema after gynecological cancer treatment: a systematic review.Frontiers in oncology · 2025Pooled it
- Sentinel Lymph Node Dissection-Novelty, Trend, or a Paradigm Shift in Surgical Decision-Making for Early Cervical Cancer?Medicina (Kaunas, Lithuania) · 2025Review
- A 5-year prospective assessment of risk factors for lower limb lymphedema after gynecologic cancer surgery.Scientific reports · 2025Article
- RELEVANT-C study: patient-reported prevalence of lower extremity lymphedema after sentinel lymph node mapping vs lymphadenectomy after surgery for early-stage cervical cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025Article
- Incidence of lymphedema related to various cancers.Medical oncology (Northwood, London, England) · 2024Review
- Use of clinical variables for preoperative prediction of lymph node metastasis in endometrial cancer.Japanese journal of clinical oncology · 2024Article
- Preventing lower limb lymphedema after pelvic lymphadenectomy with progressive resistance exercise training: A randomized controlled trial.Asia-Pacific journal of oncology nursing · 2024Article
- Multicentric development and evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial Carcinoma.Cancers · 2022Article
- Progressive resistance exercise training to prevent lower-limb lymphedema after cervical cancer surgery: A feasibility study.Asia-Pacific journal of oncology nursing · 2022Article
- Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach.Frontiers in oncology · 2022Article
- Long-Term Outcomes of Lymph Node Transfer in Secondary Lymphedema and Its Correlation with Flap Characteristics.Cancers · 2021Article
- Radiomic models for lymph node metastasis prediction in cervical cancer: can we think beyond sentinel lymph node?Translational oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundTo prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND.
methodsA prospective study in 150 patients with stage IA1-IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery.
resultsThe cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10-19%), 9.2% for moderate LLL (LVI 20-39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified.
conclusionsThe replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.